{"disease":{"id":"hodgkin-disease","name":"hodgkin disease"},"drugs":{"marketed":[{"drug_id":"cyclophosphamide","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"cyclophosphamide","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Tumor cell DNA","drug_class":"Alkylating agent","quality_score":10,"revenue":"1000.0","mechanism":"Cyclophosphamide cross-links tumor cell DNA and interferes with malignant cell growth through active alkylating metabolites."},{"drug_id":"brentuximab-vedotin","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Adcetris","generic_name":"brentuximab-vedotin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tubulin beta","drug_class":"CD30-directed Immunoconjugate [EPC]","quality_score":10,"revenue":"900","mechanism":"Adcetris works by binding to cancer cells that express CD30 and delivering a toxic payload to kill the cells."},{"drug_id":"oncovin","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Oncovin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 7, Multidrug resistance protein 1","drug_class":"","quality_score":25,"revenue":null,"mechanism":null},{"drug_id":"hydrocortisone-succinate","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Solu-Cortef","generic_name":"hydrocortisone succinate","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"vincristin","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Vincristin","company_name":"Arbeitsgemeinschaft medikamentoese Tumortherapie","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 7, Multidrug resistance protein 1","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"mechlorethamine","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Valchlor","generic_name":"MECHLORETHAMINE","company_name":"Recordati","drug_phase":"marketed","molecular_target":"","drug_class":"Alkylating Drug [EPC]","quality_score":70,"revenue":null,"mechanism":"Valchlor works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death."},{"drug_id":"hydrocortisone-acetate","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortifoam","generic_name":"HYDROCORTISONE ACETATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"dacarbazine","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Dtic-Dome","generic_name":"dacarbazine","company_name":"Bayer","drug_phase":"marketed","molecular_target":"Matrix metalloproteinase-9","drug_class":"Alkylating Drug [EPC]","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"carmustine","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gliadel","generic_name":"CARMUSTINE","company_name":"Avet Lifesciences","drug_phase":"marketed","molecular_target":"Glutathione reductase, mitochondrial","drug_class":"Alkylating Drug","quality_score":10,"revenue":null,"mechanism":"Gliadel works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and grow."},{"drug_id":"bleomycin","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Blenoxane","generic_name":"BLEOMYCIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Aspartyl/asparaginyl beta-hydroxylase","drug_class":"Cytoprotective Agent","quality_score":62,"revenue":null,"mechanism":"Bleomycin works by binding to DNA and causing strand breaks, which ultimately leads to cell death."},{"drug_id":"cortisone-acetate","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"betamethasone-acetate","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Celestone Soluspan","generic_name":"BETAMETHASONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"dexamethasone","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Decadron","generic_name":"dexamethasone","company_name":"Generic (originally Merck)","drug_phase":"marketed","molecular_target":"Annexin A1, Interleukin-4, Androgen receptor","drug_class":"Corticosteroid [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"brentuximab","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Brentuximab","company_name":"University of Arizona","drug_phase":"discontinued","molecular_target":"Tumor necrosis factor receptor superfamily member 8, Tubulin beta","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"adriacin","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"adriacin","company_name":"Chipscreen Biosciences, Ltd.","drug_phase":"phase_1","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"hydroxydaunorubicin","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunorubicin","company_name":"University of Colorado, Denver","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"cyclophosphamid","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cyclophosphamid","company_name":"Zhejiang University","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"vinblastin","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Vinblastin","company_name":"The Lymphoma Academic Research Organisation","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 7, Multidrug resistance protein 1","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"prednison","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednison","company_name":"Wen Zhang","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"methylprednisolone","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Medrol","generic_name":"methylprednisolone","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"Glucocorticoid (corticosteroid)","quality_score":62,"revenue":null,"mechanism":"Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions."},{"drug_id":"hydrocortisone","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"lomustine","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gleostine","generic_name":"LOMUSTINE","company_name":"Azurity","drug_phase":"marketed","molecular_target":"","drug_class":"Alkylating Drug [EPC]","quality_score":10,"revenue":null,"mechanism":"Gleostine works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death."},{"drug_id":"triamcinolone","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"carmustin","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Carmustin","company_name":"University Hospital Freiburg","drug_phase":"marketed","molecular_target":"Glutathione reductase, mitochondrial","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"prednisone","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Deltasone","generic_name":"prednisone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Sodium/nucleoside cotransporter 1, Glucocorticoid receptor","drug_class":"Corticosteroid [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"chlorambucil","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Leukeran","generic_name":"CHLORAMBUCIL","company_name":"Waylis","drug_phase":"marketed","molecular_target":"Cathepsin D","drug_class":"Alkylating Drug [EPC]","quality_score":10,"revenue":null,"mechanism":"Leukeran works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death."},{"drug_id":"vincristine-sulfate-pfs","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oncovin","generic_name":"Vincristine Sulfate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1","drug_class":"Vinca Alkaloid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"vincristine","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oncovin","generic_name":"vincristine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1","drug_class":"Vinca Alkaloid","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"liposomal-doxorubicin","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Liposomal Doxorubicin","generic_name":"liposomal-doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"72 kDa type IV collagenase","drug_class":"doxorubicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"procarbazine","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Matulane","generic_name":"PROCARBAZINE","company_name":"Leadiant Biosci Inc","drug_phase":"marketed","molecular_target":"","drug_class":"Alkylating Drug","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"betamethasone","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Betametasone","generic_name":"BETAMETHASONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":65,"revenue":null,"mechanism":"Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system."},{"drug_id":"doxorubicin","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doxorubicin Hydrochloride","generic_name":"doxorubicin","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Aurora kinase A","drug_class":"Anthracycline Topoisomerase Inhibitor","quality_score":80,"revenue":null,"mechanism":"Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division."},{"drug_id":"chembl-chembl1200796","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cytoxan (Lyophilized)","generic_name":"CYCLOPHOSPHAMIDE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"cyclophosphamide","quality_score":10,"revenue":null,"mechanism":"Cytoxan works by interfering with the DNA replication process in rapidly dividing cancer cells."},{"drug_id":"cortisol","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolone","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prelone","generic_name":"prednisolone","company_name":"Generic (originally Schering)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"Glucocorticoid (corticosteroid)","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"hydroxydaunomycin","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Hydroxydaunomycin","company_name":"Weill Medical College of Cornell University","drug_phase":"phase_2","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prednisolon","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"prednisolon","company_name":"Hannover Medical School","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"adriamycin","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Adriamycin","company_name":"Johann Wolfgang Goethe University Hospital","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"vincristine-sulfate-pfs","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Oncovin","generic_name":"Vincristine Sulfate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Canalicular multispecific organic anion transporter 1","drug_class":"Vinca Alkaloid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"methylprednisolon","indication_name":"Hodgkin's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Methylprednisolon","company_name":"Leiden University Medical Center","drug_phase":"marketed","molecular_target":"Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"chembl-chembl476","indication_name":"Hodgkin's Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"DACARBAZINE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Alkylating Drug [EPC]","quality_score":25,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":41,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03942263","title":"A Study to Describe Treatment Patterns and Disease Control in Participants With cHL and sALCL in Routine Clinical Practice in the Russian Federation","phase":"","overall_status":"COMPLETED","enrollment_count":2000,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT00039676","title":"Clinical, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Hematologic Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1836,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03904134","title":"Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)","phase":"NA","overall_status":"COMPLETED","enrollment_count":1753,"lead_sponsor_name":"Center for International Blood and Marrow Transplant Research","has_results":false},{"nct_id":"NCT03050268","title":"Familial Investigations of Childhood Cancer Predisposition","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT01676805","title":"Tissue Collection for Studies of Lymph Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":1295,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03935282","title":"Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors","phase":"NA","overall_status":"COMPLETED","enrollment_count":645,"lead_sponsor_name":"Wake Forest University Health Sciences","has_results":true},{"nct_id":"NCT03500133","title":"Pediatric Hodgkin Lymphoma Treatment Trial With Low Cumulative Doses of Chemotherapy Agents and Reduced Radiation.","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Hospital JP Garrahan","has_results":false},{"nct_id":"NCT02682667","title":"Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT04671693","title":"A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors.","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Centre Leon Berard","has_results":false},{"nct_id":"NCT03229200","title":"Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.","phase":"PHASE4","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":297,"lead_sponsor_name":"Pharmacyclics Switzerland GmbH","has_results":false},{"nct_id":"NCT02181738","title":"Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":294,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT02856646","title":"Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices","phase":"","overall_status":"COMPLETED","enrollment_count":290,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT03527628","title":"OPTmizing Advanced Stage HodgkIn LymphoMa patIentS Therapy","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":220,"lead_sponsor_name":"King Abdullah International Medical Research Center","has_results":false},{"nct_id":"NCT07041827","title":"Cardiotoxicity and Other Late Effects After Radiotherapy and Immuno-chemoTherapy in Non-Hodgkin lYmphoma","phase":"","overall_status":"COMPLETED","enrollment_count":217,"lead_sponsor_name":"The Netherlands Cancer Institute","has_results":false},{"nct_id":"NCT07120217","title":"Breast Cancer Risk Investigation in Grown-up Hodgkin Lymphoma Patients Treated With MBVD. Multicenter Retrospective Study on ≥200 Adult Female HL Patients Treated With ≥1 MBVD Cycle (NPLD, Bleomycin, Vinblastine, Dacarbazine). It Investigates Breast Cancer Incidence Post-treatment.","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Federico II University","has_results":false},{"nct_id":"NCT02376699","title":"Safety Study of SEA-CD40 in Cancer Patients","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":159,"lead_sponsor_name":"Seagen Inc.","has_results":false},{"nct_id":"NCT00924131","title":"Evaluation of Late Treatment Effects in Long-Term Survivors of Hodgkin's Disease Previously Treated at NIH: A Multi-Institutional Trial","phase":"","overall_status":"COMPLETED","enrollment_count":157,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02661035","title":"Allo HSCT Using RIC for Hematological Diseases","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":156,"lead_sponsor_name":"Masonic Cancer Center, University of Minnesota","has_results":false},{"nct_id":"NCT02581631","title":"An Investigational Immuno-therapy Safety and Effectiveness Study of Nivolumab in Combination With Brentuximab Vedotin to Treat Non-Hodgkin Lymphomas","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":145,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT02057185","title":"Occupational Status and Hematological Disease","phase":"","overall_status":"COMPLETED","enrollment_count":141,"lead_sponsor_name":"Gruppo Italiano Malattie EMatologiche dell'Adulto","has_results":false},{"nct_id":"NCT03598608","title":"Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":137,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":false},{"nct_id":"NCT01555892","title":"Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":136,"lead_sponsor_name":"Baylor College of Medicine","has_results":false},{"nct_id":"NCT03329950","title":"A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":132,"lead_sponsor_name":"Celldex Therapeutics","has_results":false},{"nct_id":"NCT01716806","title":"A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":131,"lead_sponsor_name":"Seagen Inc.","has_results":true},{"nct_id":"NCT00001830","title":"Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":110,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT03744676","title":"A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":104,"lead_sponsor_name":"Juno Therapeutics, a Subsidiary of Celgene","has_results":true},{"nct_id":"NCT01951885","title":"Tac, Mini-MTX, MMF Versus Tac, MTX for GVHD Prevention","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":101,"lead_sponsor_name":"Case Comprehensive Cancer Center","has_results":true},{"nct_id":"NCT04464590","title":"Interest of a Systematic One-year Monitoring by 18F-FDG PET-CT","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT04776265","title":"RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT","phase":"","overall_status":"UNKNOWN","enrollment_count":100,"lead_sponsor_name":"Grupo Argentino de Tratamiento de la Leucemia Aguda","has_results":false},{"nct_id":"NCT00520130","title":"Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":92,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT00540007","title":"Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT00571662","title":"Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":76,"lead_sponsor_name":"University of Nebraska","has_results":true},{"nct_id":"NCT02927769","title":"A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT07566377","title":"Cord Blood Transplantation in Children and Young Adults With Blood Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":71,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT06116929","title":"Hodgkin's Disease and Chemotherapy Before 40 Years","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":63,"lead_sponsor_name":"Lille Catholic University","has_results":false},{"nct_id":"NCT05244642","title":"A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":60,"lead_sponsor_name":"Akeso","has_results":false},{"nct_id":"NCT02979522","title":"A Study of Brentuximab Vedotin + Adriamycin, Vinblastine, and Dacarbazine in Pediatric Participants With Advanced Stage Newly Diagnosed Hodgkin Lymphoma","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":59,"lead_sponsor_name":"Takeda","has_results":true},{"nct_id":"NCT06254495","title":"A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":57,"lead_sponsor_name":"Seagen, a wholly owned subsidiary of Pfizer","has_results":false},{"nct_id":"NCT03755414","title":"Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":55,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT04998331","title":"A Spanish Medical Record Review of Adults With Relapsed or Refractory CD30+ Malignancies When Re-treated With Brentuximab-vedotin","phase":"","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"Takeda","has_results":false},{"nct_id":"NCT01969435","title":"Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT07449832","title":"Sperm Epigenome in Hodgkin Lymphoma","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Rennes University Hospital","has_results":false},{"nct_id":"NCT02639559","title":"Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT01158118","title":"Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT01315132","title":"A Study of Bone Marrow Transplantation Using Fully-Matched Relatives as Donors for Patients With Hematological Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":47,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","has_results":true},{"nct_id":"NCT06712810","title":"Q702 for the Treatment of Patients With Hematologic Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":46,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT00779584","title":"A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":45,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT05188755","title":"Fitness Assessment in Young Adults Recovered From Lymphoma","phase":"NA","overall_status":"COMPLETED","enrollment_count":44,"lead_sponsor_name":"University Hospital, Clermont-Ferrand","has_results":false},{"nct_id":"NCT03842696","title":"Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":43,"lead_sponsor_name":"University of Michigan Rogel Cancer Center","has_results":false},{"nct_id":"NCT01858922","title":"Chemotherapy With or Without Radiation, Low and Intermediate Risk Hodgkins Lymphoma, TXCH-HD-12A","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Baylor College of Medicine","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}